Compass Therapeutics presented new data on CTX-10726, a PD-1 x VEGF-A bispecific antibody, showing a unique mechanism where VEGF-A triggers cleavage of PD-1 receptors on T cells, enhancing immune response against tumors. This novel action could improve checkpoint inhibition effectiveness, especially in VEGF-A-rich tumor environments. A Phase 1 trial is ongoing for advanced solid tumors, with promising preclinical results combining CTX-10726 and CTX-471 showing enhanced tumor suppression. These findings suggest potential for more potent and durable cancer immunotherapy.
Compass Therapeutics' CTX-10726 bispecific antibody is the subject, with Pluang's Health sector market data as context. As of Nov 06, 2026 20:42 WIB, 51 of 150 priced Health-sector US stocks rose while 94 fell. Notable movers include TMDX at USD 77.21 with an 11.93% increase and 100% buy order activity, BKD at USD 9.55 down 11.66%, and GMED at USD 73.07 down 10.37% with 100% buy order activity.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
